title: [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
abstract: OBJECTIVE
  Treatment response and prognosis in glioblastoma (GBM) tumours can differ among patients, highlighting the growing relevance of genetic biomarkers to differentiate glioblastoma sub-types. The biomarker isocitrate dehydrogenase (IDH1) is currently receiving considerable attention. The objective of this work was to analyse the clinical and prognostic differences between glioblastomas with and without the IDH1 mutation.
  
  
  METHODS
  A retrospective study was performed on patients with GBM who underwent surgery between 2007 and 2012. The inclusion criteria were: patient age between 18-85 years who underwent surgery for the first time with complete macroscopic resection, complete adjuvant treatment with chemotherapy and radiotherapy, and a Karnofsky performance score>70.
  
  
  RESULTS
  A total of 61 patients (36 males/25 famales) were included and with a mean age of 62.3 years. An IDH1mutation was found in 14 patients (23%). Median survival in patients with the IDH1 mutation (IDH1-m) was 23.6 months compared with 11.9 months in those with the wild type IDH1 (IDH1-wt) (P=.028). Disease onset in IDH1-m patients tended to be at a younger age, 58.7 vs. 63.4 years, but this difference was not statistically significant.
  
  
  CONCLUSIONS
  Glioblastomas with IDH1-m should be considered a different entity from the IDH1-wt, as their natural history and prognosis differ. In the near future we should be classified glioblastomas based on the presence of the IDH1 mutation.
authors.affiliation: Servicio de Neurocirugía, Hospital de la Santa Creu i Sant Pau, Barcelona, España. Electronic address: cqs_7@hotmail.com.
authors.forename: Cristian
authors.initials: C
authors.lastname: de Quintana-Schmidt
authors.affiliation: Servicio de Neurocirugía, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: María Jesús
authors.initials: MJ
authors.lastname: Alvarez-Holzapfel
authors.affiliation: Servicio de Hematología (Biología Molecular), Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: Josep
authors.initials: J
authors.lastname: Nomdedeu-Guinot
authors.affiliation: Servicio de Anatomía Patológica, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: Silvia
authors.initials: S
authors.lastname: Bague-Rosell
authors.affiliation: Servicio de Oncología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: Oscar
authors.initials: O
authors.lastname: Gallego-Rubio
authors.affiliation: Servicio de Neurocirugía, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: Andreas
authors.initials: A
authors.lastname: Leidinger
authors.affiliation: Servicio de Neurocirugía, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: Laura
authors.initials: L
authors.lastname: Salgado-Lopez
authors.affiliation: Servicio de Neurocirugía, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: Joan
authors.initials: J
authors.lastname: Molet-Teixidó
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000235:genetics*; D005260:Female; D005909:Glioblastoma / Q000235:genetics*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D007521:Isocitrate Dehydrogenase
keywords: Genetic markers; Glioblastoma; Glioma; IDH; Isocitrate dehydrogenase; Isocitrato deshidrogenasa; Marcadores genéticos; Prognosis; Pronóstico; Supervivencia; Survival